Grant: Collaborative Health Research Projects
University of Toronto
$99,876.00
Platform technology for maturation of human stem cell derived cardiomyocytes and cardiotoxicity screening
EF 2017-18
Résumé
Beating heart cell cannot be sampled and expanded from human hearts, thus pharmaceutical industry is forced to usealternative methods to assess safety and efficacy of new drug candidates before they reach humans including assessmentin animal models. Animal heart cells have different functional properties than human heart cells, thus it is not possible to fullycapture both positive and negative effects of a drug during pre-clinical testing. As a result, many promising drug candidatesare abandoned early on and some dangerous drugs reach human use e.g. Vioxx that resulted in ~30,000 deaths and$5billion in settlements. This project will revolutionize the way drugs are tested before they reach humans by developing anarray of human heart tissues, starting from stem cells. We will mature the tissues so that they resemble adult human heartusing electrical field stimulation. We will engineer a fully inert platform that does not absorb or interact with the applied drugs.It will also be compatible with the equipment already in use in pharmaceutical and biological labs. Uniquely, our platform willgive readouts of many cardiac responses at once from the single tissue in a non-destructive manner. By looking at thisintegrated response from a real mature human heart tissue, we will make drug discovery process more effective ultimatelysaving cost to Canadian pharmaceutical industry and lives of Canadians by enabling discovery of safer and more effectivedrugs.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
493737-2016
Name nom
Radisic, Milica
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
99876
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Platform technology for maturation of human stem cell derived cardiomyocytes and cardiotoxicity screening
Keyword
NSERC
Application summary
Beating heart cell cannot be sampled and expanded from human hearts, thus pharmaceutical industry is forced to usealternative methods to assess safety and efficacy of new drug candidates before they reach humans including assessmentin animal models. Animal heart cells have different functional properties than human heart cells, thus it is not possible to fullycapture both positive and negative effects of a drug during pre-clinical testing. As a result, many promising drug candidatesare abandoned early on and some dangerous drugs reach human use e.g. Vioxx that resulted in ~30,000 deaths and$5billion in settlements. This project will revolutionize the way drugs are tested before they reach humans by developing anarray of human heart tissues, starting from stem cells. We will mature the tissues so that they resemble adult human heartusing electrical field stimulation. We will engineer a fully inert platform that does not absorb or interact with the applied drugs.It will also be compatible with the equipment already in use in pharmaceutical and biological labs. Uniquely, our platform willgive readouts of many cardiac responses at once from the single tissue in a non-destructive manner. By looking at thisintegrated response from a real mature human heart tissue, we will make drug discovery process more effective ultimatelysaving cost to Canadian pharmaceutical industry and lives of Canadians by enabling discovery of safer and more effectivedrugs.